Drug firm Glenmark today said it has received US health regulator's approval to sell generic Clotrimazole cream, used in treating fungal infections, in the American market.
Glenmark Generics Inc, a US-based subsidiary of the company has received Abbreviated New Drug Application (ANDA) approval from US Food and Drug Administration (USFDA) for Clotrimazole cream USP 1 per cent, Glenmark Pharmaceuticals said in a statement.
"The company will commence marketing and distribution of this product in the US market immediately," it added.
According to research firm IMS Health, Clotrimazole cream has achieved annual sales of $ 26 million in US for the fiscal ended March this year.
The product is the generic version of Taro's Clotrimazole Cream USP and will be manufactured at the company's facility in Goa.
Clotrimazole is the 16th topical semi solid product which the company would market in the US. It is an anti-fungal cream indicated for the treatment for candidiasis and tinea versicolor, a skin condition charecterised by rash on the trunk.
Glenmark's current portfolio consists of 59 products which have been cleared by USFDA for US market. The company has further 50 ANDA's pending approval with the US health regulator.
Shares of Glenmark were today trading at Rs 267.95 on Bombay Stock Exchange, up 1 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app